Irinotekan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a prodrug that is converted inside cancer cells to the active metabolite SN‑38. SN‑38 binds to topoisomerase I and stabilizes the transient DNA‑enzyme complex, preventing the re‑ligation of single‑strand DNA breaks during replication. The accumulation of unrepaired DNA damage triggers apoptosis, especially in cells that are actively dividing.

The dosing regimen for Irinotekan Kabi is individualized by the treating oncologist. It is typically calculated based on the patient’s body surface area, the specific cancer indication, and any relevant organ function parameters. Exact dose, infusion rate, and schedule must be prescribed by a qualified healthcare professional.

Safety data for Irinotekan Kabi in pregnancy and lactation are limited. The drug is generally contraindicated during pregnancy unless the potential benefit justifies the risk to the fetus. Breastfeeding is not recommended because the medication may be excreted in milk and could harm the infant.

To request Irinotekan Kabi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Irinotekan Kabi (irinotecan) and agents such as topotecan share the same mechanism of inhibiting topoisomerase I, but they differ in pharmacokinetics, spectrum of activity, and toxicity profiles. Irinotecan is commonly used for colorectal and small cell lung cancers, whereas topotecan is often selected for ovarian and small‑cell lung cancers. Choice of agent depends on tumor type, prior therapy, and patient tolerance.

Irinotekan Kabi should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vials. If the product is supplied as a lyophilized powder, reconstitute only when ready for use and follow aseptic technique.

Irinotekan Kabi is administered by intravenous infusion. The lyophilized powder is reconstituted with the appropriate diluent, then further diluted in a compatible IV solution. The infusion is given over a specified period, usually 30–90 minutes, under medical supervision with monitoring for infusion‑related reactions.

The most serious adverse events include febrile neutropenia, severe diarrhea that can progress to colitis or ileus, hepatic toxicity, and rare allergic reactions such as anaphylaxis. Prompt recognition and supportive care, including growth‑factor support for neutropenia and aggressive hydration for diarrhea, are essential to mitigate these risks.

Irinotekan Kabi should be avoided in patients with known hypersensitivity to irinotecan or any of its excipients, those with severe bone‑marrow suppression (e.g., absolute neutrophil count < 500 µL), uncontrolled infections, or active gastrointestinal obstruction. Caution is also advised for patients with significant hepatic impairment.